Figure 6From: Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoEffect of RAD001, letrozole, and tamoxifen, alone or combination, on the growth of MCF7-AROM1 and BT474-AROM3 xenografts. MCF7-AROM1 xenograft was grown in the presence of androstenedione. Once tumors reached 7 to 8 mm in diameter, animals were randomized to receive vehicle, 0.5 mg/kg (n = 6), 2 mg/kg (n = 6), or 10 mg/kg RAD001 (n = 6). Bars represent ± SEM. (B) MCF7-AROM1 xenografts were grown as described earlier. Once tumors reached 7 to 8 mm in diameter, animals were randomized to receive vehicle (n = 4), tamoxifen (n = 4), letrozole (n = 5), RAD001 (2 mg/kg) (n = 5), or a combination of agents (n = 5). (C) BT474-AROM3 grafts were grown as described earlier. Once tumors reached 7 to 8 mm in diameter, animals were randomized to receive vehicle (n = 8), tamoxifen (n = 7), letrozole (n = 8), RAD001 (2 mg/kg) (n = 8), or a combination of agents (n = 8). Tumors were measured twice weekly, and points represent mean change in tumor volumes over that of day 0. Bars represent ± SEM.Back to article page